$Veracyte (VCYT.US)$ The extensive validation of Veracyte's Decipher platform at ASCO GU 2025, supported by 17 abstracts and publication in Annals of Oncology, represents a significant strengthening of the company's market position in cancer diagnostics. The data demonstrates three important commercial advantages: First, the Decipher Prostate test's ability to predict treatment response in the NRG Oncology/RTOG 0534 trial provides a clear clinical utility case for insura...
Analysts are slightly more optimistic about Veracyte's losses per share, but expect its revenue growth to slow down substantially compared to its historical 29% growth rate. The wider industry is expected to outpace Veracyte.
The absence of any insider transactions in the past three months doesn't reveal much. Low insider ownership and previous insider selling at Veracyte sparks less enthusiasm. Investors should be aware of potential risks associated with the company.
Veracyte Stock Forum
$Veracyte (VCYT.US)$
nfa
The extensive validation of Veracyte's Decipher platform at ASCO GU 2025, supported by 17 abstracts and publication in Annals of Oncology, represents a significant strengthening of the company's market position in cancer diagnostics. The data demonstrates three important commercial advantages:
First, the Decipher Prostate test's ability to predict treatment response in the NRG Oncology/RTOG 0534 trial provides a clear clinical utility case for insura...
Revolutionary Cancer Test Results: Veracyte's Decipher Unlocks Personalized Treatment Success
Veracyte's Decipher Tests Dominate ASCO GU 2025 with Groundbreaking Cancer Detection Results
Clinical Study: Revolutionary Bladder Cancer Test Predicts Disease Progression with 33% Higher Accuracy
$ARK Innovation ETF (ARKK.US)$ :
Bought $Advanced Micro Devices (AMD.US)$ $DraftKings (DKNG.US)$ $Tempus AI (TEM.US)$
Sold $Unity Software (U.US)$ $Palantir (PLTR.US)$ $Twist Bioscience (TWST.US)$ $Veracyte (VCYT.US)$
By the way..
Palantir $PLTR is on fire this year
It's up over 109% YTD, just got included in the S&P500, and today Bank of America raised their price target to $50 a share
D. E. Shaw owns almost $500 million worth of shares, more than any...
No comment yet